Journal of Bone Oncology

Papers
(The H4-Index of Journal of Bone Oncology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
#15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma107
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma53
Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms45
Single Photon Emission Computed Tomography/X-ray Computed Tomography-based radiomics analysis for diagnosis of bone metastases in patients with breast cancer43
Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets41
Macrophage heterogeneity in bone metastasis38
MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p30
Postoperative outcomes of subaxial cervical spine metastasis: Comparison among the anterior, posterior, and combined approaches25
Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw23
From bimodal to unimodal: The transformed incidence of osteosarcoma in the United States23
State-of-the-art of minimally invasive treatments of bone metastases22
Radiomics model based on MRI to differentiate spinal multiple myeloma from metastases: A two-center study21
Predicting lung metastasis in high-grade osteosarcoma: The role of computed tomography angiography (CTA) signs with a focus on vascular wrapping and the intratumoral vascular network21
Demethylzeylasteral inhibits proliferation and metastasis of osteosarcoma cells by modulating the PI3K/AKT/Autophagy pathways20
#41. Discovery of novel tubulin code in bone metastasis of breast cancer19
Preoperative prediction of high-grade osteosarcoma response to neoadjuvant therapy based on a plain CT radiomics model: A dual-center study19
#1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma19
Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience18
0.035667896270752